MX394425B - Terapia de combinación con bromodominio e inhibidor de proteína extra terminal. - Google Patents
Terapia de combinación con bromodominio e inhibidor de proteína extra terminal.Info
- Publication number
- MX394425B MX394425B MX2018007823A MX2018007823A MX394425B MX 394425 B MX394425 B MX 394425B MX 2018007823 A MX2018007823 A MX 2018007823A MX 2018007823 A MX2018007823 A MX 2018007823A MX 394425 B MX394425 B MX 394425B
- Authority
- MX
- Mexico
- Prior art keywords
- bromodomain
- bet
- combination therapy
- terminal protein
- inhibitor
- Prior art date
Links
- 102000001805 Bromodomains Human genes 0.000 title abstract 2
- 108050009021 Bromodomains Proteins 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 101710192606 Latent membrane protein 2 Proteins 0.000 title 1
- 101710109576 Terminal protein Proteins 0.000 title 1
- 229940121649 protein inhibitor Drugs 0.000 title 1
- 239000012268 protein inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000002246 antineoplastic agent Substances 0.000 abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 abstract 3
- 229940125763 bromodomain inhibitor Drugs 0.000 abstract 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
La presente descripción se relaciona generalmente a composiciones y métodos para tratar cancere, tal como glioblastoma y linfomas no de hofgkin, u otros cánceres en los cuales el sujeto sufre de un tumor sólido avanzado, que comprende la administración de un inhibidor de bromodominio y proteína extra-terminal (BET) y por lo menos un agente quimioterapéutico, que no inhibe BET directamente. La terapia de combinación del inhibidor de BET/agente quimioterapéutico puede producir efectos sinérgicos, para de esta manera incrementar la efectividad del tratamiento de cáncer como se compara con la administración de ya sea el inhibidor de BERT o el agente quimioterapéutico solo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387359P | 2015-12-24 | 2015-12-24 | |
| US201662413763P | 2016-10-27 | 2016-10-27 | |
| PCT/US2016/067860 WO2017112703A1 (en) | 2015-12-24 | 2016-12-20 | Bromodomain and extra-terminal protein inhibitor combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018007823A MX2018007823A (es) | 2018-11-09 |
| MX394425B true MX394425B (es) | 2025-03-24 |
Family
ID=59087538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018007823A MX394425B (es) | 2015-12-24 | 2016-12-20 | Terapia de combinación con bromodominio e inhibidor de proteína extra terminal. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20170182025A1 (es) |
| EP (1) | EP3393586A4 (es) |
| JP (1) | JP2019503358A (es) |
| KR (1) | KR20180095935A (es) |
| CN (1) | CN108883311A (es) |
| AU (1) | AU2016379347A1 (es) |
| BR (1) | BR112018013063A2 (es) |
| CA (1) | CA3009642A1 (es) |
| CL (1) | CL2018001724A1 (es) |
| EA (1) | EA201891514A1 (es) |
| IL (1) | IL260222A (es) |
| MX (1) | MX394425B (es) |
| SG (2) | SG10202013249PA (es) |
| TW (1) | TW201733576A (es) |
| WO (1) | WO2017112703A1 (es) |
| ZA (1) | ZA201804223B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7171557B2 (ja) | 2016-10-27 | 2022-11-15 | セルジーン クオンティセル リサーチ，インク． | ブロモドメインおよびエクストラ末端タンパク質阻害剤を含む組合せ医薬 |
| US11332466B2 (en) | 2017-12-01 | 2022-05-17 | The Board Of Trustees Of The University Of Illinois | Pyridinone-based epigenetic modifiers and uses thereof |
| WO2019204758A1 (en) * | 2018-04-20 | 2019-10-24 | Zhiguo Zhang | Compositions and methods for treating glioblastoma by modulating a mgmt enhancer |
| CN109001638B (zh) * | 2018-06-22 | 2020-12-29 | 格林美（无锡）能源材料有限公司 | 一种快速评价正极材料包覆前后dcr的方法 |
| BR112021001019A2 (pt) * | 2018-07-23 | 2021-04-13 | Celgene Quanticel Research, Inc. | Processo para a preparação de inibidor de bromodomínio |
| WO2020169698A1 (en) * | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
| WO2021046225A1 (en) * | 2019-09-03 | 2021-03-11 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating cancer |
| CN111930838B (zh) * | 2020-07-23 | 2023-05-16 | 金陵科技学院 | 一种面向时间的分布式档案管理方法 |
| CN118715011A (zh) * | 2021-11-15 | 2024-09-27 | 伊利诺伊大学评议会 | 治疗与ras突变相关的癌症的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3081204B1 (en) * | 2012-07-13 | 2019-05-08 | Becton, Dickinson and Company Ltd. | Medical vial access device with pressure equalization and closed drug transfer system |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| CA2895905A1 (en) * | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| PL3010503T3 (pl) * | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| HRP20200341T1 (hr) * | 2013-10-18 | 2020-06-12 | Celgene Quanticel Research, Inc. | Bromodomenski (bet) inhibitori |
| US20150320754A1 (en) * | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
-
2016
- 2016-12-20 CA CA3009642A patent/CA3009642A1/en not_active Abandoned
- 2016-12-20 EP EP16879991.4A patent/EP3393586A4/en not_active Withdrawn
- 2016-12-20 SG SG10202013249PA patent/SG10202013249PA/en unknown
- 2016-12-20 WO PCT/US2016/067860 patent/WO2017112703A1/en not_active Ceased
- 2016-12-20 BR BR112018013063A patent/BR112018013063A2/pt not_active Application Discontinuation
- 2016-12-20 MX MX2018007823A patent/MX394425B/es unknown
- 2016-12-20 CN CN201680082656.XA patent/CN108883311A/zh active Pending
- 2016-12-20 AU AU2016379347A patent/AU2016379347A1/en not_active Abandoned
- 2016-12-20 JP JP2018532625A patent/JP2019503358A/ja active Pending
- 2016-12-20 KR KR1020187021390A patent/KR20180095935A/ko not_active Withdrawn
- 2016-12-20 SG SG11201805385QA patent/SG11201805385QA/en unknown
- 2016-12-20 US US15/385,763 patent/US20170182025A1/en not_active Abandoned
- 2016-12-20 EA EA201891514A patent/EA201891514A1/ru unknown
- 2016-12-23 TW TW105142897A patent/TW201733576A/zh unknown
-
2018
- 2018-06-22 CL CL2018001724A patent/CL2018001724A1/es unknown
- 2018-06-22 ZA ZA2018/04223A patent/ZA201804223B/en unknown
- 2018-06-24 IL IL260222A patent/IL260222A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10202013249PA (en) | 2021-02-25 |
| MX2018007823A (es) | 2018-11-09 |
| EP3393586A1 (en) | 2018-10-31 |
| TW201733576A (zh) | 2017-10-01 |
| CA3009642A1 (en) | 2017-06-29 |
| KR20180095935A (ko) | 2018-08-28 |
| IL260222A (en) | 2018-07-31 |
| CL2018001724A1 (es) | 2018-11-16 |
| SG11201805385QA (en) | 2018-07-30 |
| JP2019503358A (ja) | 2019-02-07 |
| AU2016379347A1 (en) | 2018-07-12 |
| ZA201804223B (en) | 2019-09-25 |
| WO2017112703A1 (en) | 2017-06-29 |
| EA201891514A1 (ru) | 2019-01-31 |
| BR112018013063A2 (pt) | 2018-12-11 |
| CN108883311A (zh) | 2018-11-23 |
| US20170182025A1 (en) | 2017-06-29 |
| EP3393586A4 (en) | 2019-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394425B (es) | Terapia de combinación con bromodominio e inhibidor de proteína extra terminal. | |
| MX2021013830A (es) | Inhibidores de ezh2 para tratar linfomas. | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201890146A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ | |
| PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
| WO2014113429A3 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| CY1125126T1 (el) | Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης | |
| ZA201603342B (en) | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| NZ700759A (en) | Combination therapy for treating cancer | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| MX2015011783A (es) | Metodos para tratar tumores solidos pediatricos. | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| MX2016010134A (es) | Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo. | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
| WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
| PH12018501790A1 (en) | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy | |
| WO2016106357A8 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| MX2021002884A (es) | Terapia de combinacion para el tratamiento de cancer de prostata. | |
| MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
| MX2015016760A (es) | Derivados de ftalazina. | |
| MX2017013668A (es) | Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer. |